Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at 2021 SITC Annual Meeting
Heidelberg, Germany, October 01, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data of its innate cell engagers have been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 10-14, 2021.
Abstract details:
- Tetravalent, bispecific innate cell engager AFM24 enhances macrophage mediated tumor cell phagocytosis
- Enhanced antibody-mediated phagocytosis and antibody-mediated cell cytotoxicity using tetravalent, bispecific innate cell engagers (ICE®) in 3D spheroids
- The bispecific innate cell engagers AFM13 (CD30/CD16A) and AFM24 (EGFR/CD16A) increase the fraction of tumor target-responsive NK cells and boost serial killing